Weiheng Hu, Jian Fang, Jun Nie, Ling Dai, Xiaoling Chen, Jie Zhang, Xiangjuan Ma, Guangming Tian, Jindi Han
OBJECTIVE: We investigated whether aprepitant, a neurokinin-1 antagonist, could decrease chemotherapy-induced nausea and vomiting (CINV) following cisplatin, when a conventional anti-emetic regimen had failed. METHODS: This was a prospective study (April 2011-April 2012) of patients with lung cancer, treated with cisplatin at the Beijing Cancer Hospital, and initially receiving granisetron, dexamethasone, and metoclopramide as anti-emetics. If patients experienced vomiting of grade ≥2 and required rescue anti-emetic medications during the first cycle, oral aprepitant was added in subsequent cycles (day 1: 125 mg; days 2-3: 80 mg once daily)...
June 2014: Cancer Chemotherapy and Pharmacology